Axogen Company Leadership
| AXGN Stock | USD 33.28 0.67 2.05% |
Axogen employs about 622 people. Management-performance analysis for Axogen Inc gives investors another way to evaluate how leadership is influencing execution, capital allocation, and operating discipline. Used properly, this analysis helps distinguish durable execution from results that may simply reflect a favorable market cycle.
| Karen Zaderej CEO CEO and President and Director |
| Angelo Scopelianos President Vice President - Research & Development |
Management Team Effectiveness
The company has return on total asset (ROA) of -2.31 % implying that it lost $2.31 for every $100 of assets on its balance sheet. This is materially lower than the sector median. Similarly, it shows a return on stockholder's equity (ROE) of -13.49 %, indicating that stockholder equity declined rather than grew.Insider Trading Activities
Insider disclosures for Axogen Inc show how people closest to the business are behaving as market expectations change. The pattern is most useful when compared with earnings releases and guidance changes rather than treated alone.
Outstanding Bonds
Corporate bonds issued by Axogen Inc matter because they shape interest expense, maturity risk, and the flexibility management has during tighter credit conditions. This is why bond analysis is not just a credit exercise; it also informs equity holders about solvency, optionality, and future capital-allocation pressure.
| US05464HAB69 Corp BondUS05464HAB69 | View | |
| AXIS SPECIALTY FIN Corp BondUS05464HAC43 | View | |
| US05463HAB78 Corp BondUS05463HAB78 | View | |
| US05463HAC51 Corp BondUS05463HAC51 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Holders Distribution
For Axogen Inc, institutional participation can be supportive or destabilizing depending on whether large holders are building conviction or reducing exposure. The opportunity for retail investors is not to imitate blindly, but to understand how large-holder positioning may affect liquidity, volatility, and timing.
Workforce Comparison
Axogen Inc is rated below average in number of employees compared to key competitors. The total workforce of Health Care industry is presently estimated at about 25,138. Axogen holds roughly 622 in number of employees claiming about 2.47% of equities under Health Care sector.
The company has Profit Margin (PM) of -7.0 %, which implies a breakdown in cost control or pricing power. This is materially lower than the sector median. Similarly, it shows Operating Margin (OM) of -16.0 %, which suggests that the company is unable to cover operating costs from its revenue. Insider Trading History
The insider trade history for Axogen Inc reveals whether executives were buying or selling during key price moves. Investors focus on trades outside normal pay timelines, as those are more likely to reflect genuine conviction.
Notable Stakeholders
Stakeholders matter for Axogen because not every influential participant is a shareholder acting with the same objective or time horizon. Used properly, stakeholder review supports staying aware of the people and incentives that may be shaping key decisions behind the scenes.
| Michael Dale | CEO President | Profile | |
| Karen Zaderej | CEO and President and Director | Profile | |
| Angelo Scopelianos | Vice President - Research & Development | Profile | |
| Erick DeVinney | Vice President of Clinical and Translational Sciences | Profile | |
| Peter Mariani | Ex CFO | Profile | |
| Marc Began | General VP | Profile | |
| Gregory Davault | VP Marketing | Profile | |
| Maria Martinez | Chief Human Resource Officer | Profile | |
| Lindsey CPA | Chief Officer | Profile | |
| CFA CPA | Chief Officer | Profile | |
| Isabelle Billet | Chief Strategy and Business Development Officer | Profile | |
| Jens Kemp | Chief Officer | Profile | |
| Todd Puckett | Vice Operations | Profile | |
| Harold MBA | Vice Relations | Profile | |
| Craig Swandal | Vice Operations | Profile | |
| Bradley JD | G Officer | Profile | |
| Ed Joyce | Director Relations | Profile | |
| Michael Donovan | Vice Operations | Profile | |
| Doris Quackenbush | Vice Sales | Profile | |
| Ivica MD | Chief Officer | Profile | |
| Harold Tamayo | Vice Relations | Profile |
Management Information & Data Sources
Axogen is a small-cap company across Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care. Management effectiveness is reflected in operating results, capital allocation choices, and margin durability. Margin trends and reinvestment returns reveal whether management is creating or eroding shareholder value. CEO is Michael Dale with 622 employees and 21 reported executives.
For Axogen Inc, this section uses periodic company reporting and market reference feeds and standardizes the results for cross-period comparison. Intraday timing differences may exist. Insider and management fields are mapped from published filings and company disclosures.
This content is curated and reviewed by:
Rifka Kats - Member of Macroaxis Editorial BoardWorkforce Efficiency and Productivity
Workforce efficiency at Axogen Inc can help investors judge how effectively labor resources are being converted into revenue and profit over time. The business is commonly classified in the Healthcare sector and the Medical Devices industry.
Axogen Manpower Efficiency
Return on Axogen Manpower
| Revenue Per Employee | 362.1K | |
| Revenue Per Executive | 10.7M | |
| Net Loss Per Employee | 25.2K | |
| Net Loss Per Executive | 747.8K | |
| Working Capital Per Employee | 155.7K | |
| Working Capital Per Executive | 4.6M |